Device Trial Radar · NCT01923805
Vitagel Revision Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Jun 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Apr 2013
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- The Cleveland ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stryker Nordic
- First posted
- Aug 16, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective study will evaluate the effectiveness of Vitagel (VG) in reducing blood loss associated with Revision Total Knee Arthroplasty (RTKA) procedures by assessing the patient's change in hemoglobin/hematocrit. Transfusion rates with the use of VG compared to the current standard of care will also be evaluated. The effectiveness of VG to potentially reduce pain, and increase return to function and quality of life will be assessed through the modified Knee Injury and Osteoarthritis Outcome Score (Modified KOOS), the Numerical Assessment Pain Scale (NAPS), and the SF-12 health survey. Analgesic use will be recorded post-operatively.
Conditions
- Failed Total Knee Arthroplasty
Interventions
VitagelDevice
Vitagel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Transfusion RequirementsTime frame: Participants will be followed for the duration of hospital stay, an expected average of 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Cleveland Clinic
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.